| Sera Prognostics is a women's health company. Co.'s primary commercial product, the PreTRM test, is a commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during week 18 or 20 of gestation that provides a prediction of the expectant mother's risk of delivering spontaneously before 37 weeks' gestation. Co. is discovering and developing several additional biomarker tests to predict other conditions of pregnancy, such as preeclampsia, and gestational diabetes, among others. The SERA YTD return is shown above.
The YTD Return on the SERA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SERA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SERA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.